Equative case

Navidea Biopharmaceuticals Files Appeal in CRG Case

Retrieved on: 
Thursday, December 1, 2022
Biotechnology, Health, Professional Services, Pharmaceutical, Legal, Judgement, NYSE American, History, Technetium-99m, Anonymous Online Speakers v. United States District Court for the District of Nevada, Macrophage, Biopharmaceutical, Therapy, Health, Annual report, Disease, District court, NYSE, Risk, Research, Equative case, Coronavirus, Appeal, Pharmaceutical industry

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No.
  • v. Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc., with the 14th Court of Appeals of Texas for review by the appellate court.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
  • The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.

Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees

Retrieved on: 
Thursday, September 1, 2022
Professional Services, Health, Legal, Research, Science, Pharmaceutical, Biotechnology, Technetium-99m, Judgement, Securities Exchange Act of 1934, NYSE, Securities Act of 1933, Research, District court, Therapy, Macrophage, Disease, Coronavirus, Decision-making, NYSE American, Risk, SEC, Court, Biopharmaceutical, History, Equative case, Annual report, CRG, Global Analyst Research Settlements, Review, Forward-looking statement, Health, Pharmaceutical industry, Bookkeeping

v. Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc., awarding Capital Royalty Group (CRG) $2,572,937.61 in attorneys fees on their breach of contract claims against Navidea and Macrophage Therapeutics (MT).

Key Points: 
  • v. Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc., awarding Capital Royalty Group (CRG) $2,572,937.61 in attorneys fees on their breach of contract claims against Navidea and Macrophage Therapeutics (MT).
  • v. Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc., and by pursuing a suit against CRG in the State of Ohio.
  • Navidea is disappointed in the Courts ruling and does not believe the law and the facts presented at the trial support the ruling against it.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.